首页 按字顺浏览期刊浏览卷期浏览
Since Novartis' COX-2 inhibitor lumiracoxib ['Prexige'] has failed to demonstrate featu...
Since Novartis' COX-2 inhibitor lumiracoxib ['Prexige'] has failed to demonstrate features differentiating it from the class leader celecoxib ['Celebrex; Pfizer/Pharmacia'], it could have limited market success,